The Wall Street Journal: Merck to purchase biotech Afferent for at least $500 million 0 10.06.2016 03:47 MarketWatch.com Merck & Co. has agreed to purchase biotechnology company Afferent Pharmaceuticals, whose lead drug candidate is being evaluated as a treatment for refractory, chronic cough and idiopathic pulmonary fibrosis with cough. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
